ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Silence Therapeutics PLC

Silence Therapeutics PLC (SLN)

6,17
-0,68
(-9,93%)
Geschlossen 06 Juni 10:00PM
6,17
0,00
(0,00%)
Nach Börsenschluss: 10:30PM

Silence Therapeutics PLC (SLN) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
6,17
( -9,93% )
Gebot
5,85
Fragen
7,20
Volumen
160.480
6,07 Tagesbereich 6,73
4,19 52-Wochen-Bereich 8,40
Marktkapitalisierung
Handelsende
6,85
Handelsbeginn
6,73
Letzte Trade
5
@
6.29
Letzter Handelszeitpunkt
Finanzvolumen
US$ 1.007.466
VWAP
6,2778
Durchschnittliches Volumen (3 Mio.)
US$ 326.755
Ausgegebene Aktien
47.233.949
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-4,33
Gewinn pro Aktie (EPS)
-1,61
Erlöse (LTM)
839k
Nettogewinn (LTM)
-75,04M

Über Silence Therapeutics PLC

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran ... Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
London, United Kingdom
Gegründet
1994
Silence Therapeutics PLC is listed in the Healthcare sector of the NASDAQ with ticker SLN. The last closing price for Silence Therapeutics was US$6,85. Over the last year, Silence Therapeutics shares have traded in a share price range of US$ 4,19 to US$ 8,40.

Silence Therapeutics currently has 47.233.949 shares in issue. The market capitalisation of Silence Therapeutics is US$291,43 million. Silence Therapeutics has a price to earnings ratio (PE ratio) of -4.33.

SLN Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.58-8.592592592596.756.9256.171996196.62575941DR
4-0.68-9.927007299276.857.455.742048806.54619908DR
12-0.83-11.857142857178.44.753219866.57823209DR
26-0.97-13.58543417377.148.44.192944876.18210403DR
520.6812.38615664855.498.44.192112596.17956624DR
1560.5710.17857142865.627.721.9721466910.06849858DR
260-20.33-76.716981132126.528.581.9714339710.37014399DR

SLN - Frequently Asked Questions (FAQ)

What is the current Silence Therapeutics PLC share price?
The current share price of Silence Therapeutics PLC is US$ 6,17
How many Silence Therapeutics PLC shares are in issue?
Silence Therapeutics PLC has 47.233.949 shares in issue
What is the market cap of Silence Therapeutics PLC?
The market capitalisation of Silence Therapeutics PLC is USD 291,43M
What is the 1 year trading range for Silence Therapeutics PLC share price?
Silence Therapeutics PLC has traded in the range of US$ 4,19 to US$ 8,40 during the past year
What is the PE ratio of Silence Therapeutics PLC?
The price to earnings ratio of Silence Therapeutics PLC is -4,33
What is the cash to sales ratio of Silence Therapeutics PLC?
The cash to sales ratio of Silence Therapeutics PLC is 391,27
What is the registered address of Silence Therapeutics PLC?
The registered address for Silence Therapeutics PLC is 12 Hammersmith Grove, London, Greater London, W6 7AP
What is the Silence Therapeutics PLC website address?
The website address for Silence Therapeutics PLC is www.silence-therapeutics.com
Which industry sector does Silence Therapeutics PLC operate in?
Silence Therapeutics PLC operates in the Biotechnology & Life Sciences sector

SLN Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen